Univest
Univest
  • Markets

Remus Pharmaceuticals (REMUS) Share Price rises 9.19% as stock trades at Rs 1,010

  • October 8, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Remus Pharmaceuticals Share Price
Remus Pharmaceuticals Ltd. (REMUS) share price rose to Rs 1,010 today, up 9.19% from the previous close. Market cap was Rs 1,098.39 crore.

Remus Pharmaceuticals Share Price is trading at Rs 1,010, up 9.19% from the previous close of Rs 925, with market capitalisation of Rs 1,098.39 crore. The move places Remus Pharmaceuticals Share Price among the day’s notable gainers, though no company-specific catalyst is established. Univest figures confirm the price action, but they do not point to a specific company trigger. For readers tracking Remus Pharmaceuticals Share Price Today, the relevant points are simple: the stock opened above the previous close, moved to the day’s high at Rs 1,010 and held that level as of 14 October 2026 at 1:22:56 PM IST. This Remus Pharmaceuticals Share Price news note focuses on what is verified, not on speculation. Investors watching Remus Pharmaceuticals Share Price can next monitor the valuation profile, sector positioning and peer comparisons that sit behind the day’s share price gain.

Table of Contents

Toggle
  • Remus Pharmaceuticals Share Price Today: Price Action Analysis
  • Remus Pharmaceuticals Ltd. (REMUS) Fundamental Analysis
  • Sector and Industry Context
  • Peer Comparison
  • Why Investors Are Watching Remus Pharmaceuticals
  • About Remus Pharmaceuticals
  • Frequently Asked Questions
    • What is Remus Pharmaceuticals Share Price today?
    • Why is Remus Pharmaceuticals rising today?
    • What does the latest price action show for Remus Pharmaceuticals Share Price?
    • How does Remus Pharmaceuticals compare on valuation?
    • What are the key profitability ratios for Remus Pharmaceuticals Share Price?
    • What are EPS, book value and dividend yield for Remus Pharmaceuticals?
    • How does Remus Pharmaceuticals Share Price compare with peers?
    • Which sector and industry does Remus Pharmaceuticals belong to?
  • Track Remus Pharmaceuticals Share Price on Univest

Remus Pharmaceuticals Share Price Today: Price Action Analysis

Metric Value
Current Price Rs 1,010
Previous Close Rs 925
Today's Move Rs 85 (+9.19%)
Open Rs 931
High Rs 1,010
Low Rs 931
Market Capitalisation Rs 1,098.39 crore
Market Cap Category Small Cap

Remus Pharmaceuticals Ltd. (REMUS) rose to Rs 1,010 from the previous close of Rs 925, a move of Rs 85 or 9.19%. The stock opened at Rs 931, reached a high of Rs 1,010, recorded a low of Rs 931.

Remus Pharmaceuticals Share Price rose steadily through the session and is last traded at Rs 1,010, matching the day’s high. The stock opened at Rs 931, stayed above the previous close of Rs 925, and printed a day low of Rs 931. That leaves the move as an intraday share price rise of Rs 85, or 9.19%, with no reversal back toward the opening level. For Remus Pharmaceuticals Share Price Today, the latest move is a clean price action event rather than a late-session drift. The market capitalisation of Rs 1,098.39 crore gives the gain a clear size context. In Remus Pharmaceuticals Share News, this is the factual move to note: price, open, high, low and the day’s change are all aligned with a firm advance. The next section turns to Remus Pharmaceuticals Fundamental Analysis for the valuation and profitability backdrop.

Remus Pharmaceuticals Ltd. (REMUS) Fundamental Analysis

Metric Value
Market Capitalisation Rs 1,098.39 crore
P/E Ratio 29.47x
P/B Ratio 3.11x
ROE 15.22%
ROCE 18.64%
EPS Rs 31.39
Book Value Per Share Rs 297.86
Dividend Yield 0.11%

Remus Pharmaceuticals Ltd. (REMUS) fundamental metrics show P/E 29.47x, P/B 3.11x, ROE 15.22%, ROCE 18.64%. Taken on their own, these numbers offer context rather than a trading signal.

Remus Pharmaceuticals Ltd. has a market capitalisation of Rs 1,098.39 crore and falls in the Small Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 29.47x, P/B at 3.11x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 15.22% and ROCE of 18.64%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 31.39, book value per share of Rs 297.86, dividend yield of 0.11%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 22.17x, median ROE of 4.14%, median ROCE of 6.09%. They set out the fundamental picture and are not a rating on the stock.

Sector and Industry Context

Metric Value
Sector Trading
Industry Trading
Benchmark Scope same industry
Company P/E Ratio 29.47x
Benchmark Median P/E 22.17x
Benchmark Average P/E 80.99x
Benchmark P/E Range 0.14x to 2,898.86x
Company P/B Ratio 3.11x
Benchmark Median P/B 1.39x
Company ROE 15.22%
Benchmark Median ROE 4.14%
Company ROCE 18.64%
Benchmark Median ROCE 6.09%
Company Market Capitalisation Rs 1,098.39 crore
Benchmark Median Market Cap Rs 52.86 crore

Remus Pharmaceuticals Ltd. (REMUS) operates in the Trading sector, within the Trading industry.

Remus Pharmaceuticals Ltd. (REMUS) has a P/E ratio of 29.47x, which is above the benchmark median of 22.17x, a difference of +32.93%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Remus Pharmaceuticals Ltd. (REMUS) has a ROE of 15.22%, which is above the benchmark median of 4.14%, a difference of +267.63%. Remus Pharmaceuticals Ltd. (REMUS) has a ROCE of 18.64%, which is above the benchmark median of 6.09%, a difference of +206.08%.

Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.

Peer Comparison

Company Symbol Market Cap (Cr) P/E P/B ROE (%) ROCE (%)
Adani Enterprises Ltd. ADANIENT 3,56,164.42 48.99 3.87 15.07 13.3
Aegis Logistics Ltd. AEGISLOG 50,887.98 39.05 7.4 20.71 19.76
ADITYA INFOTECH LIMITED CPPLUS 50,704.4 112.23 15.24 25.68 29.48
Premier Energies Ltd. PREMIERENE 41,218.8 24.54 8.59 42.6 33.72
Redington Ltd. REDINGTON 30,575.2 18.02 2.89 13.6 18.96

Remus Pharmaceuticals Ltd. (REMUS) has a P/E ratio of 29.47x compared with the displayed peer median of 39.05x. The comparison is relative and should not be read as a recommendation. Its ROE of 15.22% compares with a peer median of 20.71% across the companies shown in the table. ROCE stood at 18.64% versus the displayed peer median of 19.76%, providing a capital-efficiency comparison. Remus Pharmaceuticals Ltd. (REMUS) has a market capitalisation of Rs 1,098.39 crore. All 5 peers shown have a larger market capitalisation.

Why Investors Are Watching Remus Pharmaceuticals

  • Remus Pharmaceuticals Share Price rose 9.19% today and traded at Rs 1,010, making the move notable on a day of clear price action.
  • Remus Pharmaceuticals Share Price Today is supported by a market capitalisation of Rs 1,098.39 crore, which gives the move a defined size context.
  • Remus Pharmaceuticals Fundamental Analysis shows a P/E of 29.47, P/B of 3.11, ROE of 15.22% and ROCE of 18.64%.
  • Remus Pharmaceuticals Share Price sits above the industry median on P/E, ROE and ROCE in the same-industry benchmark.
  • Remus Pharmaceuticals Stock News today is best read through verified ratios, peer position and the confirmed intraday rise rather than speculation.

About Remus Pharmaceuticals

Remus Pharmaceuticals Ltd. operates in the Trading sector and Trading industry. The company description provided for this note does not include segment mix, product details or revenue split, so this section stays with the verified company context. For readers tracking Remus Pharmaceuticals Share Price, the important business label is clear: the company is classified in Trading, which is also the benchmark group used in the sector comparison. That makes Remus Pharmaceuticals Share Price relevant for investors who follow Trading sector names on NSE and BSE and compare them using P/E, P/B, ROE and ROCE. The market capitalisation of Rs 1,098.39 crore, along with EPS of Rs 31.39 and book value of Rs 297.86, gives a compact picture of the business profile behind the stock. Univest uses this context to frame Remus Pharmaceuticals Share Price without adding assumptions about operations or growth.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).

Frequently Asked Questions

What is Remus Pharmaceuticals Share Price today?

Ans. Remus Pharmaceuticals Share Price is Rs 1,010, up 9.19% from the previous close of Rs 925. The stock also carries a market capitalisation of Rs 1,098.39 crore, which gives the move clear size context.

Why is Remus Pharmaceuticals rising today?

Ans. Univest figures confirm the price action, but they do not point to a specific company trigger. Remus Pharmaceuticals Share Price rose Rs 85 intraday and touched a high of Rs 1,010 during the trading session.

What does the latest price action show for Remus Pharmaceuticals Share Price?

Ans. Remus Pharmaceuticals Share Price opened at Rs 931, stayed above the previous close of Rs 925 and traded at the day’s high of Rs 1,010. That sequence confirms a straightforward intraday share price rise.

How does Remus Pharmaceuticals compare on valuation?

Ans. Remus Pharmaceuticals Share Price carries a P/E of 29.47 and a P/B of 3.11. In the same-industry benchmark, the P/E is above the median of 22.17 and the P/B is above the median of 1.39.

What are the key profitability ratios for Remus Pharmaceuticals Share Price?

Ans. The latest Univest figures show ROE at 15.22% and ROCE at 18.64%. Both are above the same-industry medians, which adds context to Remus Pharmaceuticals Share Price beyond today’s gain.

What are EPS, book value and dividend yield for Remus Pharmaceuticals?

Ans. EPS is Rs 31.39, book value is Rs 297.86 and dividend yield is 0.11%. These three figures help frame Remus Pharmaceuticals Share Price in terms of earnings per share, asset backing and payout history.

How does Remus Pharmaceuticals Share Price compare with peers?

Ans. Remus Pharmaceuticals Share Price sits below higher-valuation peers such as ADITYA INFOTECH LIMITED on P/E, while its ROE and ROCE remain competitive versus Redington and Adani Enterprises. That creates a balanced peer picture.

Which sector and industry does Remus Pharmaceuticals belong to?

Ans. Remus Pharmaceuticals is placed in the Trading sector and Trading industry. That is the same benchmark group used for its sector comparison, making Remus Pharmaceuticals Share Price easier to read against listed peers.

Track Remus Pharmaceuticals Share Price on Univest

Use Remus Pharmaceuticals Ltd. (REMUS) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.

You can track Remus Pharmaceuticals Share Price on Univest for live share price updates, valuation ratios, market capitalisation, 52-week levels and market insights. The Remus Pharmaceuticals Share Price page also helps readers compare the stock with sector peers, review the latest ratios and follow price action in one place. Univest keeps the focus on verified figures and clear company context, which is useful when Remus Pharmaceuticals Share Price is moving sharply intraday. For investors checking Remus Pharmaceuticals Share News, Univest offers a simple way to revisit the company’s P/E, P/B, ROE, ROCE, EPS, book value and dividend yield alongside the day’s price rise.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply